independently

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary…

2 days ago

Full product line of TrinaTracker Vanguard series now Carbon Footprint certified

CHANGZHOU, China, Oct. 2, 2025 /PRNewswire/ -- TrinaTracker, a provider of smart solar tracking solutions under Trinasolar, announced that it…

5 days ago

WEB3 Meets Edtech as Geninfinity Introduces Blockchain Identity Tools for All Users

Geninfinity introduces a secure system that lets users create digital identities and manage their educational records independently. This new feature…

3 months ago